Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday, 3 March 2025 and said it expects double-digit revenue and core profit growth in its commercial pharmaceuticals unit in the full year, ...

Eli Lilly remains a favorite among billionaires, ranking 11th in top stock picks. The pharmaceutical giant’s 2024 revenue ...